RxDoctor Payments Data

Renee McManus

Psychiatric/Mental Health · North Lima, OHNPI 1265789796

Payments from drug & device makers

$1,786in general payments, 2019–2025

Across 78 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$632
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$331
  • Sanofi$135
  • GSK$125
  • AstraZeneca$124
  • Axsome Therapeutics, Inc.$113
  • plus $327 from 5 others

What the payments were for

  • Food & beverage$1,73797%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,786 in reported general payments places this provider in the 70th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$8,875
Medicare patients
28
Services billed
137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole14$39,975
RexultiBrexpiprazole24$35,977
VyvanseLisdexamfetamine Dimesylate21$7,942
Clozapine69$2,488
Aripiprazole44$2,240
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine59$1,999
Quetiapine Fumarate136$1,695
Divalproex Sodium41$1,616
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$1,359
Bupropion XlBupropion Hcl86$1,008
Oxcarbazepine24$763
Clonazepam89$697
Clomipramine Hcl13$677
Ziprasidone Hcl20$629
Venlafaxine Hcl ErVenlafaxine Hcl39$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$632$75,95138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in North Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →